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Peroxisome proliferator-activated receptor α and estrogen are 
believed to be involved in metabolic changes leading to obesity. 
To test this relationship, we divided female wildtype and 
PPARα-deficient mice fed on a high fat diet into the following 
groups: mock-operated, ovariectomized (OVX), and E2-treated. 
The visceral white adipose tissue and plasma cholesterol levels 
were increased significantly in wild type OVX and decreased in 
the E2-treated group, but interestingly not in PPARα-deficient 
mice. The mRNA levels of lipoprotein lipase in adipose tissue 
were also increased in only wild type OVX and decreased sig-
nificantly in E2-treated mice. These novel results suggest the pos-
sibility of signaling crosstalk between PPARα and E2, causing 
obesity in vivo. [BMB reports 2009; 42(2): 91-95]
INTRODUCTION
Obesity is a disorder of energy balance, influenced by factors 
such as gender, nutrition, and genetics. Excess caloric intake 
induces the elevation of plasma triglycerides (TG) and choles-
terol concentration. Elevated levels of TGs are stored in adi-
pose tissue, resulting in hypertrophy and hyperplasia of adipo-
cytes (1).
    Estrogen, a steroid hormone, has a significant biological ef-
fect on adipose tissue. Female rodents that undergo ovar-
iectomy become obese (2). Estrogen treatment reverses this 
condition, suggesting the involvement of estrogen in lipid me-
tabolism in adipose tissue. Treatment of ovariectomized ani-
mals with estrogen decreased lipoprotein lipase (LPL) activity 
in adipose tissue (3, 4). LPL is postulated to reduce the release 
of free fatty acids, decrease TG assimilation, and diminish the 
size of adipocytes and body fat content.
    Although several transcription factors can promote adipo-
genesis, their direct implication in mammalian obesity is not 
fully substantiated. Peroxisome proliferator-activated receptors 
(PPARs), members of the nuclear receptor superfamily, are one 
such example (5). PPARs form heterodimers with the retinoid 
X receptor (RXR) and bind to specific PPAR response elements 
in the promoter region of target genes (6). These play an im-
portant role in the regulation of genes involved in lipid uti-
lization and storage, lipoprotein metabolism, adipocyte differ-
entiation, and insulin action. PPARα target genes include those 
involved in the hydrolysis of plasma TG; LPL and apolipopro-
tein CIII (apoCIII) (7), fatty acid uptake and binding; fatty acid 
transport protein and acyl-CoA synthetase (8), and fatty acid 
β-oxidation; acyl CoA oxidase, enoyl-CoA hydratase/3-hydrox-
yacyl-CoA dehydrogenase, and 3-ketoacyl-CoA thiolase (9). 
PPARγ regulates genes involved in adipocyte differentiation, 
lipid storage, glucose metabolism, adipocyte fatty acid-binding 
protein, LPL, and leptin (10).
    Lipid metabolism is affected by many hormonal signals, in-
cluding classical hormones such as insulin, thyroid hormone, 
retinoic acid, glucocorticoids and estrogen, as well as other se-
creted molecules such as tumor necrosis factor-α and leptin. 
Previous in vitro reports demonstrated molecular mechanisms 
which involve crosstalk between the thyroid hormone receptor 
and PPAR through their common partner RXR (11), as well as 
between the estrogen receptor and PPARα through their com-
mon binding to an estrogen response element (12). However, 
the correlation between PPARα and estrogen on obesity is yet 
to be characterized in vivo.
    In the present study, we investigated the correlation between 
PPARα and estrogen using female wildtype and PPARα-defi-
cient mice, fed a high fat diet for 16 weeks. Furthermore, to elu-
cidate a possible mechanism for the contribution of estrogen to 
adiposity, we studied the patterns of expression of enzymes re-
lated to lipid storage, LPL, PPARγ, and leptin in white adipose 
tissue (WAT).
RESULTS AND DISCUSSION
Previous reports demonstrated that ovariectomized (OVX) fe-
male rodents became obese and that estrogen replacement re-
versed this condition (2, 13). In the present study, ovar-
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E2 Status Surgery n
Body weight (B.W.) Uterine Wt(mg/g B.W.)
Visceral WAT Wt
(g/g B.W.)

































  6.13 ± 1.35
  1.20 ± 0.41
13.93 ± 1.55
  4.30 ± 0.85








Uterine weights were expressed in mg relative to body weight (mg/g B.W.) and visceral white adipose tissue (WAT) in g relative to body weight (g/g 
B.W.). n = number of mice examined. Results were expressed as mean ± standard deviation for all values. 
aP ＜ 0.005 different from NOH group of PPARα+/+ mice.
bP ＜ 0.0005 different from OH group of PPARα+/+ mice.
Table 1. Effect of estrogen (E2) on body, uterine, and visceral WAT weight (Wt) in PPARα+/+ and PPARα-/- mice
Fig. 1. Effect of estrogen on fat accumulation in PPARα+/+ and 
PPARα-/- mice. (a) Gross finding of WAT in N, NOH; O, OH; E, 
OHE. (b) Visceral WAT weights relative to body weight (g of 
WAT/ g of body weight). NOH = non-ovariectomy, OH = ovar-
iectomy, OHE = E2-treated OH ovariectomy.
Fig. 2. Effect of estrogen on plasma cholesterol level in PPARα+/+
and PPARα-/- mice. Plasma concentration of cholesterol (mg/dl) at 
week 16. NOH = non-ovariectomy, OH = ovariectomy, OHE = 
E2-treated OH ovariectomy.
iectomy-atrophied uterus, as evidenced by uterine weight, did 
not cause significant changes in body weight between the dif-
ferent groups studied (Table 1). In PPARα+/+ mice, WAT was 
higher in the ovariectomized (OH) group than in the non-ovar-
iectomized (NOH) group by 38% (P ＜ 0.005). Furthermore, 
WAT was lower in the E2-treated OH group (OHE) than in the 
OH group by 72% (P ＜ 0.0005). However, PPARα-/- mice did 
not display increased fat accumulation compared to the OH 
group. Instead, their WAT mass decreased by 35% compared 
to the NOH group (Table 1, Fig. 1).
    E2 has the ability to lower total plasma cholesterol both in 
animal models fed on a high fat diet and in women (14). 
Interestingly, the results of the present study showed that the 
changes in plasma cholesterol levels were similar to that of 
WAT weight, although all PPARα-/- mice displayed higher bas-
al levels of plasma cholesterol than PPARα+/+ mice, as pre-
vious reported (15). PPARα+/+ OVX mice showed an increase 
of 44% over the NOH group and a decrease of 28% following 
E2 treatment, but PPARα-/- mice did not (Fig. 2). There were no 
significant changes in the levels of TG, HDL, and LDL be-
tween the different genotypes studied (data not shown).
    To determine the cause of these phenotypic differences be-
tween PPARα+/+ and PPARα-/- mice, we investigated the ex-
pression of genes related to lipid storage and differentiation in 
the WAT of mice belonging to all experimental groups using 
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Fig. 3. RT-PCR analyses of LPL, PPARγ, and leptin expression in 
WAT in PPARα+/+ and PPARα-/- mice. NOH = non-ovariectomy,
OH = ovariectomy, OHE = E2-treated OH ovariectomy. Data 
represent mean and standard deviation of at least three in-
dependent experiments. Vertical bars represent the level of mRNA 
of different genes. Each value was normalized to β-actin (a) were 
expressed again as values (b) relative to each normalized gene 
expression of the NOH group (b=a/values of PPARα+/+ or 
PPARα-/- NOH ×100). Black bar = NOH, hatched bar = OH, 
dotted bar = OHE.
RT-PCR techniques. The levels of LPL mRNA expression, one 
of the important pathways by which estrogen suppresses fat 
accumulation, showed differential expression in the PPARα+/+ 
and PPARα-/- mice. Similar to the observed change in WAT 
weight, PPARα+/+ OVX mice demonstrated greater LPL mRNA 
expression than the PPARα+/+ NOH group by 5% and the 
PPARα+/+ OHE group exhibited lower LPL expression by 65% 
(P ＜ 0.005). PPARα-/- OVX mice that did not gain WAT mass 
showed a 39% decrease rather than an increase (P ＜ 0.05) in 
LPL mRNA expression (Fig. 3a).
    The PPARγ mRNA level showed a similar pattern of change 
in LPL expression between the different groups studied, al-
though this was not obvious. PPARγ expression increased by 
14% in the PPARα+/+ OH group over the NOH group and de-
creased by 29% in the OHE group (P ＜ 0.05). However, 
PPARα-/- mice showed a 20% and 36% decrease in the OH 
and OHE groups (P ＜ 0.05), respectively (Fig. 3b). On the oth-
er hand, changes in leptin level between genotypes were not 
significantly different. All OVX mice showed a decrease in lep-
tin expression over each NOH group regardless of genotype, 
namely 26% and 17% in PPARα+/+ and PPARα-/- mice, 
respectively. Also, all E2-treated mice showed an 85% and 
51% decrease in PPARα+/+ and PPARα-/- mice (P ＜ 0.05), re-
spectively (Fig. 3c). Collectively, we speculate that the differ-
ence between estrogen effects on obesity between PPARα+/+ 
and PPARα-/- female mice might be related to the direct or in-
direct effect of estrogen on expression of LPL and PPARγ 
mRNA levels.
    The possibility of signal crosstalk between estrogen and 
PPAR has stimulated much interest because of their similar 
DNA target sequences (ERE, TGACCT N3 AGGTCA, PPRE, 
TGACCT N TCACCT), which Keller et al. (12) and Nunez et 
al. (16) reported based on in vitro studies. Due to the fact that 
estrogen and PPAR have a clinical impact on lipid metabolism, 
we hypothesized that crosstalk between the two factors may 
participate in the regulation of obesity in vivo. In the present 
study, we investigated the correlation of PPARα and estrogen 
on adiposity by comparing OVX and E2-treated PPARα+/+ and 
PPARα-/- mice.
    In PPARα+/+ mice, ovariectomy induced increases in WAT 
mass and plasma cholesterol level, which were reversed by E2 
treatment. Such findings agree with those of previous reports, 
which concluded that estrogen decreased total serum choles-
terol (17) and fat deposition, especially in visceral adipose tis-
sues (18). However, the increases in WAT and plasma choles-
terol level following ovariectomy were not observed in 
PPARα-/- mice, suggesting that PPARα and estrogen might act 
together to regulate obesity.
    Concurrent with the changes in WAT and plasma cholester-
ol levels between the different genotypes, PPARα+/+ OVX 
mice showed increased mRNA levels of LPL, an enzyme that is 
down-regulated by estrogen, and PPARγ, a transcription factor 
that increases LPL in adipose tissue. The mRNA levels of both 
genes were decreased in the OHE group. The observed change 
in LPL level according to E2 status was consistent with other re-
ports (3, 4). Interestingly, however, the mRNA levels of those 
genes in PPARα-/- mice were not increased in the OH group. 
This inferred that the difference in effect exerted by E2 between 
the PPARα+/+ and PPARα-/- mice may be due to the direct or 
indirect action of LPL and PPARγ. LPL is a PPAR target gene, 
based on the identification of a PPRE in the LPL promoter (5). 
Selective PPARα and PPARγ ligands increase LPL expression in 
the liver and adipose tissue, respectively (19). However, 
Ranganathan and Kern (20) recently reported that direct PPARγ 
activation actually reduced LPL activity in cultured adipocytes 
by a posttranslational inhibitory mechanism. Therefore, PPAR 
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regulation of LPL activity involves a complex interplay of dif-
ferent mechanisms. 
    Our study also supported the complex interplay of PPAR in 
the regulation of LPL activity by showing different results in 
regulating adiposity between PPARα+/+ and PPARα-/- mice. 
Furthermore, estrogen showed a negative regulatory activity 
on the LPL promoter through putative activating protein-1 
(AP-1 protein(s)) (21), and PPARs interfere with the AP-1 and 
nuclear factor-κB (NF-κB) signaling pathway by preventing the 
binding of AP-1 and NF-κB proteins to their target sequences 
(22). Therefore, it was inferred that a certain unknown signal 
crosstalk between PPARα and estrogen might be responsible 
for the different results of LPL activity between PPARα+/+ and 
PPARα-/- mice in this study. 
    On the other hand, the degree of mRNA expression level of 
leptin was similar between genotypes and was not affected by 
estrogen in either the PPARα+/+ or PPARα-/- group. Expression 
of leptin can be increased by overfeeding as part of a feedback 
mechanism to limit further food intake and weight gain (23). 
Because PPARα-/- mice are not hyperphagic (24, 25) the geno-
type did not affect leptin levels. Also, the leptin level was not 
significantly altered by estrogen because estrogen did not di-
rectly regulate leptin secretion or its effects on fat mass (26). 
This supported the finding that the expression of leptin did not 
significantly affect differential fat accumulation between the 
PPARα genotypes.
    In conclusion, our data suggests that estrogen-controlled 
adiposity depends on PPARα, and that LPL and PPARγ might 
be involved in the mechanism. These results are the first to 
suggest the possibility of signal crosstalk between PPARα and 
estrogen on adiposity in vivo. However, further study is re-
quired to uncover the exact mechanism causing the different 
effects of estrogen between PPARα+/+ and PPARα-/- mice, and 




Specific pathogen-free C57BL/6N×129/Sv homozygous PPARα 
wildtype (+/+) and deficient (-/-) mice were initially introduced 
from the National Institute of Health (Bethesda, MD, USA) and 
bred at the Korea Research Institute of Bioscience and 
Biotechnology. Female PPARα+/+ and PPARα-/- mice were treat-
ed similarly as follows: at sexual maturity (5 weeks old), female 
mice were bilaterally ovariectomized (OVX) or underwent a 
mock operation after anesthetization with avertin (0.02 μg/g). 
Two weeks after surgery, some of the OVX mice were im-
planted with a subcutaneous slow-release hormone pellet 
(Innovative Research of America, Sarasota, Florida, USA) twice 
for 16 weeks (at day 1 and day 61). The pellets were designed to 
release 12 μg/day exogenous E2 as 17β-estradiol for 60 days. 
The animals were fed on a high fat diet containing 15% fat, 
1.25% cholesterol, 0.5% Na-cholate (Oriental Yeast CO, Ltd, 
Japan) for 16 weeks. Their body weights were measured weekly 
and blood was collected at week one, four, eight, and sixteen 
following initiation of the high fat diet. After 16 weeks, the ani-
mals were sacrificed by cervical dislocation, and the liver and 
WAT were excised, weighed, snap frozen in liquid nitrogen, 
and stored at -70oC until further use. The entire uterus was col-
lected from each mouse to assess in vivo exposure to E2. Serosal 
fat was removed with a pair of fine scissors. After removal of lu-
minal fluid, the entire uterus was wet-weighed. The Ethics 
Committee of Korea Research Institute of Bioscience and 
Biotechnology approved of all animal use.
Blood chemical analyses
Blood was collected from the retro-orbital venous plexus with 
heparinized capillary tubes. Plasma was obtained by cen-
trifugation of the whole blood at 10,786 g at 4oC for 10 min 
and stored at -70oC before further analysis. Plasma total cho-
lesterol, TG, high-density lipoprotein (HDL) and low-density 
lipoprotein (LDL) were measured using an automatic blood 
chemical analyzer (7020, Hitachi, Japan).
Reverse transcriptase-polymerase chain reaction analysis
Total RNA was isolated from WAT of all mice using TRIZOL 
(Gibco BRL, Rockville, MD, USA) according to the manu-
facturer’s recommended procedure. cDNA was synthesized 
from 1 μg of total RNA using moloney murine leukemia virus 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA). 2 μl of 
synthesized total cDNA were used for PCR. The sense and anti-
sense primer sequences were: 5'-CAGCAAGACCTTCGTGGTG 
A-3' and 3'-GTACAGGGCGGCCACAAGT-5' for LPL (84 bp 
product); 5'-TGACTCATACATAAAGTC-3' and 3'-CATCTAATT 
CCAGTGCAT-5' for PPARγ (485 bp product); 5'-GTGCTGGA 
GACCCCTGTGTCG-3' and 3'-AGAATGGGGTGAAGCCCAG 
GA-5' for leptin (207 bp product); and 5'-TGGAATCCTGTGG 
CATCCATGAAAC-3' and 3'-TAAAACGCAGCTCAGTAACAGT 
CCG-5' for β-actin (349-bp product). The amplification products 
were separated electrophoretically on a 1.5% agarose gel con-
taining ethidium bromide. UV-stimulated fluorescence was cap-
tured using a digital videocamera and quantitated with the Bio 
1D software (Vilber Lourmat, Marine, Cedex, France). Linearity 
of the PCR was tested by amplifying each cDNA at various num-
bers of cycles and was found to be between 25 and 35 cycles. 
All experimental values were normalized to β-actin.
Statistics
Data were presented as the mean ± standard deviation and stat-
istical significance was determined by the Student’s t-test. 
Differences were considered significant when P was less than 0.05.
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